Drug Profile
Anumigilimab - CSL Behring
Alternative Names: Anti-CSF3 monoclonal antibody; Anti-G-CSFR mAb; CSL-324; CSL324 G-CSFR; G-CSF antagonists - CSL BehringLatest Information Update: 28 Nov 2023
Price :
$50
*
At a glance
- Originator MuriGen Therapeutics; Zenyth Therapeutics
- Developer CSL Behring
- Class Anti-inflammatories; Antirheumatics; Monoclonal antibodies; Skin disorder therapies
- Mechanism of Action Granulocyte colony-stimulating factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hidradenitis suppurativa; Palmoplantar pustulosis
- Discontinued Rheumatoid arthritis
Most Recent Events
- 28 Nov 2023 No recent reports of development identified for phase-I development in Hidradenitis suppurativa in Australia (IV, Infusion)
- 28 Nov 2023 No recent reports of development identified for phase-I development in Hidradenitis suppurativa in Denmark (IV, Infusion)
- 28 Nov 2023 No recent reports of development identified for phase-I development in Hidradenitis suppurativa in Germany (IV, Infusion)